Holen Sie sich die Stockscreener-App
23.90
0.59%
0.14
Handel nachbörslich:
24.02
0.12
+0.50%
Schlusskurs vom Vortag:
$23.76
Offen:
$23.1
24-Stunden-Volumen:
4.94M
Relative Volume:
0.90
Marktkapitalisierung:
$2.57B
Einnahmen:
$45.97M
Nettoeinkommen (Verlust:
$-508.80M
KGV:
-4.3613
EPS:
-5.48
Netto-Cashflow:
$-382.65M
1W Leistung:
+16.93%
1M Leistung:
+109.28%
6M Leistung:
+218.67%
1J Leistung:
+22.50%
1-Tages-Spanne:
$21.89
$24.83
1-Wochen-Bereich:
$20.31
$26.98
52-Wochen-Spanne:
$5.90
$26.98
Intellia Therapeutics Inc Stock (NTLA) Company Profile
Firmenname
Intellia Therapeutics Inc
Sektor
Branche
Telefon
857-285-6200
Adresse
40 ERIE STREET, CAMBRIDGE, MA
Vergleichen Sie NTLA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NTLA
Intellia Therapeutics Inc
|
23.90 | 2.55B | 45.97M | -508.80M | -382.65M | -5.48 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-06 | Hochstufung | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2025-04-21 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-03-05 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-02-28 | Herabstufung | Goldman | Neutral → Sell |
| 2025-02-28 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-01-27 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-23 | Herabstufung | Goldman | Buy → Neutral |
| 2024-02-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-04-13 | Eingeleitet | Canaccord Genuity | Buy |
| 2023-03-21 | Eingeleitet | Bernstein | Outperform |
| 2023-03-14 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-02-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-01-24 | Hochstufung | Citigroup | Sell → Neutral |
| 2023-01-19 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-10-11 | Eingeleitet | Morgan Stanley | Overweight |
| 2022-09-21 | Eingeleitet | JP Morgan | Overweight |
| 2022-09-01 | Eingeleitet | Citigroup | Sell |
| 2022-06-17 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2022-06-16 | Eingeleitet | BofA Securities | Buy |
| 2022-04-28 | Eingeleitet | Credit Suisse | Outperform |
| 2022-02-18 | Eingeleitet | William Blair | Outperform |
| 2022-02-07 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2022-01-31 | Eingeleitet | Cowen | Outperform |
| 2022-01-07 | Eingeleitet | Piper Sandler | Overweight |
| 2021-10-05 | Eingeleitet | Guggenheim | Buy |
| 2021-09-24 | Eingeleitet | Stifel | Buy |
| 2021-06-28 | Bestätigt | H.C. Wainwright | Buy |
| 2021-06-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-05-07 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2021-05-04 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-03-04 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-12-22 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-10-27 | Eingeleitet | Truist | Buy |
| 2020-10-14 | Eingeleitet | Wells Fargo | Overweight |
| 2020-09-18 | Eingeleitet | Goldman | Buy |
| 2020-02-28 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2020-02-14 | Herabstufung | Wedbush | Outperform → Neutral |
| 2019-11-01 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2019-07-09 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-06-10 | Eingeleitet | ROTH Capital | Neutral |
| 2019-05-03 | Hochstufung | Wedbush | Neutral → Outperform |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2018-11-02 | Herabstufung | Wedbush | Outperform → Neutral |
| 2018-10-29 | Eingeleitet | Credit Suisse | Neutral |
| 2018-09-21 | Eingeleitet | Raymond James | Mkt Perform |
| 2018-05-15 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2018-03-08 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2017-11-01 | Bestätigt | Jefferies | Buy |
| 2017-06-22 | Fortgesetzt | Jefferies | Buy |
| 2017-03-28 | Eingeleitet | Chardan Capital Markets | Buy |
| 2016-08-05 | Hochstufung | Jefferies | Hold → Buy |
Alle ansehen
Intellia Therapeutics Inc Aktie (NTLA) Neueste Nachrichten
Can Intellia Therapeutics Inc. (38I) stock test all time highsJuly 2025 Selloffs & Safe Entry Momentum Tips - newser.com
Analyzing drawdowns of Intellia Therapeutics Inc. with statistical tools2025 Stock Rankings & Growth Oriented Trading Recommendations - newser.com
StockWatch: Novo Nordisk Raises MASH Bet with Up-to-$5.2B Akero Acquisition - Genetic Engineering and Biotechnology News
How Intellia Therapeutics Inc. (38I) stock performs in easing cyclesQuarterly Profit Report & Daily Market Momentum Tracking - newser.com
Is Intellia Therapeutics Inc. showing signs of accumulation2025 Valuation Update & High Conviction Buy Zone Alerts - newser.com
What to expect from Intellia Therapeutics Inc. in the next 30 daysJuly 2025 Recap & Free Daily Entry Point Trade Alerts - newser.com
Risk adjusted return profile for Intellia Therapeutics Inc. analyzed2025 Risk Factors & Expert Approved Trade Ideas - newser.com
What Recent Gene Editing Breakthroughs Mean for the Future of Intellia Therapeutics Stock - Yahoo Finance
Why Intellia Therapeutics (NTLA) Is Up 22.8% After Promising Gene-Editing Data at ESGCT 2025 and Phase 3 Enrollment - Yahoo Finance
A Look at Intellia Therapeutics’s Valuation Following Breakthrough ATTR Data and HAELO Study Milestone - Yahoo Finance
Published on: 2025-10-12 05:21:21 - newser.com
Cyndeo Wealth Partners LLC Invests $101,000 in Intellia Therapeutics, Inc. $NTLA - MarketBeat
Intellia Therapeutics Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Will Intellia Therapeutics Inc. (38I) stock profit from automation wave2025 Fundamental Recap & AI Driven Stock Reports - newser.com
Intellia Therapeutics (NTLA): Revisiting Valuation After Analyst Upgrades and Hereditary Angioedema Program Milestones - Sahm
Intellia Therapeutics upgraded by Citizens JMP on HAE opportunity, shares rise 6% - MSN
CRISPR Market Size, Share, Recent Developments, Growth - openPR.com
Using flow based indicators on Intellia Therapeutics Inc.Weekly Stock Analysis & Community Consensus Picks - newser.com
Intellia Therapeutics Hits Day High with 19.72% Surge in Stock Price - Markets Mojo
Intellia Therapeutics Hits Day High with 10.71% Surge in Stock Price - Markets Mojo
Intellia Therapeutics Hits New 52-Week High at $26.45 - Markets Mojo
Intellia Therapeutics Stock Soars on Gene-Editing Breakthrough – Analysts Eye 70–100% Upside - ts2.tech
Intellia Therapeutics (NTLA) Soars 19.7%: Is Further Upside Left in the Stock? - Yahoo Finance
Intellia Therapeutics (NTLA) Soars to New High as Analysts Trigger ‘Buy’ - Yahoo Finance
Intellia Therapeutics' (NTLA) Sell (D-) Rating Reaffirmed at Weiss Ratings - MarketBeat
Intellia Therapeutics (NTLA) Upgraded to Buy: Here's What You Should Know - sharewise.com
Intellia Therapeutics (NTLA) Soars on CRISPR Breakthroughs – Latest Updates & Stock Outlook - ts2.tech
Is Intellia Therapeutics Inc 38I a good long term investmentRetail Investor Activity & Actionable Entry & Exit Points Daily - earlytimes.in
Intellia Therapeutics (NASDAQ:NTLA) Trading 6.6% HigherHere's What Happened - MarketBeat
Intellia Therapeutics (NTLA) Surges Over 23% in Market Trading - GuruFocus
Wall Street Analysts Predict a 63.7% Upside in Intellia Therapeutics (NTLA): Here's What You Should Know - sharewise.com
On Course: Intellia CSO Offers Clinical Update of In Vivo Gene Editing Therapies at ESGCT - Genetic Engineering and Biotechnology News
Healthcare Stocks Are Rising: Here Are 2 With Even More Upside Ahead - AOL.com
Is Intellia Therapeutics (NTLA) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Supercharged Gene-Editing: Intellia’s 63% Rally Just The Start, Say Analysts - NAI500
Intellia Therapeutics Inc Stock Analysis and ForecastBear Market Strategies & Easy Tools to Analyze Your Investment Risk - earlytimes.in
1 Stock Up by 63% This Year That Could Double, According to Wall Street - Yahoo Finance
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Intellia Therapeutics stock hits 52-week high at 21.49 USD By Investing.com - Investing.com Canada
Intellia Therapeutics (NTLA) Sees Stock Rise Following Analyst U - GuruFocus
Intellia Therapeutics (NASDAQ:NTLA) Hits New 1-Year High on Analyst Upgrade - MarketBeat
Intellia Therapeutics stock hits 52-week high at 21.49 USD - Investing.com
Intellia Therapeutics (NASDAQ:NTLA) Stock Rating Upgraded by Citizens Jmp - MarketBeat
Intellia Therapeutics (NASDAQ:NTLA) Upgraded by JMP Securities to Market Outperform Rating - MarketBeat
JMP Securities Upgrades Intellia Therapeutics (NTLA) - Nasdaq
What Analysts Are Saying About Intellia Therapeutics Stock - Benzinga
Intellia Therapeutics (NTLA) Upgraded by JMP Securities to Marke - GuruFocus
Published on: 2025-10-06 06:23:31 - newser.com
Intellia Therapeutics (NTLA) Sees Strong Gains as Ark Invest Inc - GuruFocus
Cathie Wood's Ark Invest weekly recap: adds more Alibaba, Baidu, Kodiak AI, Intellia to its funds (ARKK:BATS) - Seeking Alpha
Citizens upgrades Intellia Therapeutics stock rating on strong HAE outlook - Investing.com
Finanzdaten der Intellia Therapeutics Inc-Aktie (NTLA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Intellia Therapeutics Inc-Aktie (NTLA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Dube Michael P | VP, Chief Accounting Officer |
Oct 01 '25 |
Sale |
17.38 |
1,871 |
32,518 |
55,266 |
| CHASE WILLIAM J | Director |
Aug 20 '25 |
Buy |
10.03 |
100,000 |
1,003,000 |
134,693 |
| Dulac Edward J III | EVP, Chief Financial Officer |
Jul 23 '25 |
Sale |
14.02 |
7,462 |
104,617 |
106,062 |
| Clark Eliana | EVP, Chief Technical Officer |
Jul 01 '25 |
Sale |
9.82 |
1,022 |
10,036 |
95,369 |
| Dube Michael P | VP, Chief Accounting Officer |
Jul 02 '25 |
Sale |
9.95 |
2,503 |
24,905 |
57,137 |
| GOODMAN JESSE | Director |
Jun 30 '25 |
Sale |
9.56 |
1,547 |
14,789 |
25,906 |
| GOODMAN JESSE | Director |
Jul 01 '25 |
Sale |
9.23 |
1,547 |
14,279 |
24,359 |
| Bhanji Muna | Director |
Apr 29 '25 |
Sale |
8.50 |
265 |
2,252 |
19,203 |
| Clark Eliana | EVP, Chief Technical Officer |
Mar 04 '25 |
Sale |
8.99 |
679 |
6,104 |
95,369 |
| BASTA JAMES | EVP, General Counsel |
Mar 04 '25 |
Sale |
8.99 |
2,572 |
23,122 |
111,925 |
5.15%
1.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):